Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTate & Lyle Regulatory News (TATE)

Share Price Information for Tate & Lyle (TATE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 674.50
Bid: 674.00
Ask: 674.50
Change: 1.00 (0.15%)
Spread: 0.50 (0.074%)
Open: 674.00
High: 678.50
Low: 672.50
Prev. Close: 673.50
TATE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

New Commercial and Food Innovation Centre in Chicago

19 Oct 2010 15:30

19 October 2010 - Tate & Lyle PLC

Tate & Lyle to establish new Commercial and Food Innovation Centre in Chicago, Illinois

Tate & Lyle PLC ("Tate & Lyle") announces today that it is to establish a new Commercial and Food Innovation Centre in Chicago, Illinois.

In May 2010, Tate & Lyle announced the implementation of a new global organisational structure as part of its clear intention to focus, fix and grow its business. The establishment of this new Centre, bringing Tate & Lyle's innovation group and speciality food ingredients business in North America together in a new, state-of-the-art facility in Chicago, with enhanced access to customers, represents the next logical step in the development of this new structure.

The new Centre will be the global headquarters of Tate & Lyle's Innovation and Commercial Development group and the regional headquarters for the Speciality Food Ingredients business in North America. The Centre will also act as the base for those US employees with global responsibilities and, accordingly, the President of the Bulk Ingredients global business unit, and his support staff, will be located there. These groups are all currently located in Decatur, Illinois, and, therefore, employees from these groups in due course will be relocating to Chicago. In total, approximately 160 positions will be located in the new Centre.

The 110,000 square-foot, three-storey building, to be leased by Tate & Lyle and situated in the Hoffman Estates area of Chicago, will feature laboratories, a demonstration kitchen, and sensory testing, analytical and pilot plant facilities. The new Centre will be specifically designed to meet customers' functional, formulation and nutritional needs and to accelerate the process of bringing new products to market.

The new Centre is expected to be operational by the end of 2011.

Tate & Lyle expects to recognise exceptional costs of up to US$32 million in connection with relocation and restructuring associated with this initiative, and capital expenditure of US$26 million in relation to the fit-out of the new Centre, both to be incurred largely in the year ending 31 March 2012.

Javed Ahmed, Chief Executive of Tate & Lyle said:

"Meeting our customers' product development and innovation needs is at the very heart of our business. The new Commercial and Food Innovation Centre in Chicago will enable our scientists, marketing, sales and technical experts to collaborate more closely with our customers, and to respond rapidly to their needs for innovative food ingredients and solutions.

"Tate & Lyle's clear priority is to grow its Speciality Food Ingredients business, supported by cash generated from Bulk Ingredients. This investment represents another important step in positioning Tate & Lyle to deliver on its strategic objectives as we focus, fix and grow our business."

End

For more information contact Tate & Lyle PLC:

Chris McLeish, Group VP, Investor and Media Relations
Tel: +44 (0) 20 7977 6211 or Mobile: +44 (0) 7919 102 730
William Baldwin-Charles, Head of Media Relations
Tel: +44 (0) 20 7977 6165 or Mobile: +44 (0) 7810 151 425

About Tate & Lyle:

Tate & Lyle is a global provider of ingredients and solutions to the food, beverage and other industries, operating from more than 45 production facilities around the world. Through our large-scale, efficient manufacturing plants, we turn raw materials into distinctive, high quality ingredients for our customers. Our ingredients and solutions add taste, texture, nutrition and increased functionality to products that millions of people around the world use or consume every day.

Tate & Lyle's range of leading branded food ingredients includes SPLENDA® Sucralose, PROMITOR™ Dietary Fiber and STA-LITE® Polydextrose. Tate & Lyle also produces branded industrial ingredients including Bio-PDO™, Ethylex® and Sta-Lok® paper starches; and staple ingredients such as high fructose corn syrup, ethanol, citric acid and basic starches. In addition to providing a wide range of ingredients our Innovation and Commercial Development Group supports customers by providing product development, technical advice and proprietary consumer insight studies.

Tate & Lyle is listed on the London Stock Exchange under the symbol TATE.L. American Depositary Receipts trade under TATYY. In the year to 31 March 2010, Tate & Lyle employed 5,666 people in its subsidiaries and joint ventures, and sales totalled £3.6 billion. http://www.tateandlyle.com.

SPLENDA® is a trademark of McNeil Nutritionals, LLC

Copyright Business Wire 2010

Date   Source Headline
4th Jun 20245:22 pmRNSAnnual Financial Report and Notice of AGM
4th Jun 202411:00 amRNSDirector/PDMR Shareholding
3rd Jun 202412:00 pmRNSTotal Voting Rights
30th May 202412:15 pmRNSHolding(s) in Company
23rd May 20247:00 amRNSFinal Results
23rd May 20247:00 amRNSSale of remaining interest in Primient JV to KPS
20th May 20241:00 pmRNSDirectorate Change
17th May 20243:30 pmRNSHolding(s) in Company
14th May 20243:30 pmRNSHolding(s) in Company
13th May 202410:00 amRNSHolding(s) in Company
8th May 20243:15 pmRNSHolding(s) in Company
1st May 20242:30 pmRNSTotal Voting Rights
25th Apr 20243:45 pmRNSHolding(s) in Company
24th Apr 20247:00 amRNSDirectorate Change
22nd Apr 20242:30 pmRNSDirector/PDMR Shareholding
19th Apr 202410:15 amRNSHolding(s) in Company
17th Apr 20244:15 pmRNSHolding(s) in Company
17th Apr 202410:30 amRNSHolding(s) in Company
15th Apr 202410:30 amRNSHolding(s) in Company
10th Apr 20243:45 pmRNSHolding(s) in Company
8th Apr 202411:15 amRNSHolding(s) in Company
5th Apr 20243:45 pmRNSHolding(s) in Company
4th Apr 20244:15 pmRNSHolding(s) in Company
4th Apr 202412:30 pmRNSHolding(s) in Company
4th Apr 202411:30 amRNSDirector/PDMR Shareholding
2nd Apr 202412:45 pmRNSTotal Voting Rights
2nd Apr 202411:30 amRNSHolding(s) in Company
28th Mar 202411:45 amRNSHolding(s) in Company
25th Mar 202411:45 amRNSHolding(s) in Company
21st Mar 20244:10 pmRNSHolding(s) in Company
20th Mar 20243:00 pmRNSHolding(s) in Company
20th Mar 202412:00 pmRNSHolding(s) in Company
19th Mar 20242:00 pmRNSHolding(s) in Company
13th Mar 20244:00 pmRNSHolding(s) in Company
12th Mar 20244:24 pmRNSHolding(s) in Company
12th Mar 20244:22 pmRNSHolding(s) in Company
7th Mar 20247:00 amRNSDirectorate Change
4th Mar 20242:00 pmRNSDirector/PDMR Shareholding
4th Mar 20241:45 pmRNSHolding(s) in Company
28th Feb 20242:30 pmRNSHolding(s) in Company
21st Feb 20247:00 amRNSTrading Statement
1st Feb 202412:00 pmRNSTotal Voting Rights
11th Jan 20241:00 pmRNSDirector/PDMR Shareholding
2nd Jan 202412:00 pmRNSBlock listing Interim Review
8th Dec 202311:45 amRNSDirector/PDMR Shareholding
6th Dec 202310:30 amRNSHolding(s) in Company
27th Nov 20234:15 pmRNSHolding(s) in Company
23rd Nov 20232:30 pmRNSHolding(s) in Company
20th Nov 202310:00 amRNSHolding(s) in Company
9th Nov 20237:00 amRNSHalf-year Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.